{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:10:58Z","timestamp":1790687458717,"version":"4.1.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.clml.2018.03.007","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T14:30:38Z","timestamp":1521383438000},"page":"311-320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways"],"prefix":"10.1016","volume":"18","author":[{"given":"Ali","family":"Dehghanifard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Kaviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Abroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshad","family":"Mehdizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajedeh","family":"Saiedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhosein","family":"Maali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasan","family":"Ghaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.03.007_bib1","first-page":"99","article-title":"Association of chromosomal translocation and miRNA expression with the pathogenesis of multiple myeloma","volume":"16","author":"Saki","year":"2014","journal-title":"Cell J"},{"key":"10.1016\/j.clml.2018.03.007_bib2","first-page":"87","article-title":"Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806)","volume":"21","author":"Bergsagel","year":"1962","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.clml.2018.03.007_bib3","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1182\/blood-2006-07-038703","article-title":"CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib4","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2003-06-2151","article-title":"Nuclear factor-\u03baB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis","volume":"103","author":"Bharti","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/leu.2012.272","article-title":"PSGL-1\/selectin and ICAM-1\/CD18 interactions are involved in macrophage-induced drug resistance in myeloma","volume":"27","author":"Zheng","year":"2012","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.clml.2018.03.007_bib6","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminhematol.2012.05.005","article-title":"Relapsed\/refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance","volume":"49","author":"Siegel","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2018.03.007_bib7","doi-asserted-by":"crossref","first-page":"10317","DOI":"10.1021\/jm300434z","article-title":"Molecular mechanisms of acquired proteasome inhibitor resistance","volume":"55","author":"Kale","year":"2012","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.clml.2018.03.007_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrclinonc.2012.15","article-title":"Latest advances and current challenges in the treatment of multiple myeloma","volume":"9","author":"Mahindra","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.007_bib9","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1200\/JCO.2005.02.4950","article-title":"Development of effective new treatments for multiple myeloma","volume":"23","author":"Anderson","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.007_bib10","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.03.007_bib11","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1586\/erm.10.31","article-title":"Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis","volume":"10","author":"Balakumaran","year":"2010","journal-title":"Exp Rev Mol Diagn"},{"key":"10.1016\/j.clml.2018.03.007_bib13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0037-1963(01)90021-6","article-title":"Targeted therapy for multiple myeloma","volume":"38","author":"Anderson","year":"2001","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2018.03.007_bib14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib15","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.leu.2402924","article-title":"Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms","volume":"17","author":"Nefedova","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.007_bib16","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1038\/sj.onc.1204833","article-title":"Biologic sequelae of interleukin-6 induced PI3-K\/Akt signaling in multiple myeloma","volume":"20","author":"Hideshima","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2018.03.007_bib17","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","article-title":"Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma","volume":"95","author":"Dankbar","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0609.2001.00348.x","article-title":"Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma","volume":"66","author":"Sezer","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2018.03.007_bib19","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.V93.5.1658","article-title":"Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines","volume":"93","author":"Damiano","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib20","doi-asserted-by":"crossref","first-page":"e55841","DOI":"10.1371\/journal.pone.0055841","article-title":"Very late antigen-4 (\u03b14\u03b21 integrin) targeted PET imaging of multiple myeloma","volume":"8","author":"Soodgupta","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2018.03.007_bib21","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood-2003-12-4218","article-title":"The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion\u2013mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase","volume":"104","author":"Schmidmaier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib22","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1158\/1535-7163.MCT-06-0684","article-title":"Wnt3\/RhoA\/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism","volume":"6","author":"Kobune","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2018.03.007_bib23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.semcancer.2010.04.003","article-title":"Adhesion molecules\u2014the lifelines of multiple myeloma cells","volume":"30","author":"Katz","year":"2010","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clml.2018.03.007_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11010-013-1856-7","article-title":"Adhesion to fibronectin induces p27Kip1 nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells","volume":"386","author":"Fei","year":"2014","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.clml.2018.03.007_bib25","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/10245330310001621305","article-title":"The regulatory mechanism of IL-6-dependent proliferation of human myeloma cells","volume":"8","author":"Abroun","year":"2003","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2018.03.007_bib26","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1182\/blood-2011-10-386789","article-title":"Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma","volume":"120","author":"Kuhn","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.clml.2018.03.007_bib28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1196\/annals.1377.002","article-title":"SFK\u2013STAT pathway: an alternative and important way to malignancies","volume":"1086","author":"Hayakawa","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clml.2018.03.007_bib29","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1158\/0008-5472.CAN-07-6696","article-title":"Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1","volume":"68","author":"Ahn","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2018.03.007_bib30","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/sj.onc.1203477","article-title":"Control of myeloid differentiation and survival by Stats","volume":"19","author":"Smithgall","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2018.03.007_bib31","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2004-10-4083","article-title":"A\u00a0rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma","volume":"105","author":"Li","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib32","doi-asserted-by":"crossref","first-page":"6328","DOI":"10.1038\/sj.onc.1208782","article-title":"Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals","volume":"24","author":"Ishikawa","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2018.03.007_bib33","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2004-04-1322","article-title":"Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells","volume":"106","author":"Dimberg","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib34","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","article-title":"Interleukin-6 signaling pathway in targeted therapy for cancer","volume":"38","author":"Guo","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2018.03.007_bib35","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.leukres.2012.02.016","article-title":"Interleukin-6, osteopontin and Raf\/MEK\/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholines","volume":"36","author":"Yosifov","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.03.007_bib36","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/blood.V99.6.2172","article-title":"Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6","volume":"99","author":"Ishikawa","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib37","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2003-07-2187","article-title":"Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor \u03b1","volume":"103","author":"Abroun","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib38","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1038\/bcj.2013.63","article-title":"A\u00a0novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases","volume":"3","author":"Hayakawa","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2018.03.007_bib39","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/ijc.26152","article-title":"A\u00a0small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells","volume":"130","author":"Lin","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2018.03.007_bib40","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/leu.2011.175","article-title":"The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells","volume":"25","author":"Monaghan","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.007_bib41","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1038\/sj.onc.1206315","article-title":"Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-\u03baB (RelB\/p50) in myeloma cells","volume":"22","author":"Landowski","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2018.03.007_bib42","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s00018-013-1545-4","article-title":"NF-kappaB pathways in hematological malignancies","volume":"71","author":"Gasparini","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clml.2018.03.007_bib43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2018.03.007_bib44","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1038\/sj.onc.1204623","article-title":"The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications","volume":"20","author":"Hideshima","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2018.03.007_bib45","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00001813-200007000-00001","article-title":"Proteasome inhibitors as anti-cancer agents","volume":"11","author":"Murray","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clml.2018.03.007_bib46","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/bjc.2013.711","article-title":"An anti-leishmanial thiadiazine agent induces multiple myeloma cell apoptosis by suppressing the nuclear factor kappaB signalling pathway","volume":"110","author":"Chen","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2018.03.007_bib47","doi-asserted-by":"crossref","first-page":"45380","DOI":"10.1074\/jbc.M108294200","article-title":"NF-\u03baB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene","volume":"276","author":"Kurland","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2018.03.007_bib48","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1158\/1535-7163.MCT-09-0645","article-title":"The novel, proteasome-independent NF-\u03baB inhibitor V1810 induces apoptosis and cell cycle arrest in multiple myeloma and overcomes NF-\u03baB\u2013mediated drug resistance","volume":"9","author":"Meinel","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2018.03.007_bib49","doi-asserted-by":"crossref","first-page":"e95846","DOI":"10.1371\/journal.pone.0095846","article-title":"NF-kappa B modulation is involved in celastrol induced human multiple myeloma cell apoptosis","volume":"9","author":"Ni","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2018.03.007_bib50","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1182\/blood-2007-11-124156","article-title":"Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors","volume":"112","author":"Sharma","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ccr.2007.07.010","article-title":"Multiple myeloma: lusting for NF-kappaB","volume":"12","author":"Gilmore","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2018.03.007_bib52","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.exphem.2012.10.002","article-title":"Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-\u03baB activity","volume":"41","author":"Salem","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2018.03.007_bib53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2184.2012.00814.x","article-title":"Caspase-mediated programmed cell death pathways as potential therapeutic targets in cancer","volume":"45","author":"Wen","year":"2012","journal-title":"Cell Prolif"},{"key":"10.1016\/j.clml.2018.03.007_bib54","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1-phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2018.03.007_bib55","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1158\/0008-5472.CAN-05-0850","article-title":"FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance","volume":"65","author":"Yasui","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2018.03.007_bib56","first-page":"65","article-title":"Triptolide inhibits the growth and metastasis of solid tumors","volume":"2","author":"Yang","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2018.03.007_bib57","first-page":"489","article-title":"Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k\/Akt\/NF-kappaB pathways in human multiple myeloma cells","volume":"22","author":"Yang","year":"2008","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.clml.2018.03.007_bib58","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s10238-004-0053-0","article-title":"Blockade of the Ras pathway by manumycin, a farnesyltransferase inhibitor, overcomes the resistance of myeloma plasma cells to Fas-induced apoptosis","volume":"4","author":"Frassanito","year":"2005","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.clml.2018.03.007_bib59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0959-437X(98)80061-0","article-title":"Ras signalling and apoptosis","volume":"8","author":"Downward","year":"1998","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.clml.2018.03.007_bib60","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1128\/MCB.21.16.5299-5305.2001","article-title":"NF-kappaB signals induce the expression of c-FLIP","volume":"21","author":"Micheau","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clml.2018.03.007_bib61","doi-asserted-by":"crossref","first-page":"e70430","DOI":"10.1371\/journal.pone.0070430","article-title":"Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells","volume":"8","author":"M\u00fcller","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2018.03.007_bib62","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1038\/bcj.2013.17","article-title":"Stimulation of toll-like receptor-1\/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells","volume":"3","author":"Abdi","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2018.03.007_bib63","doi-asserted-by":"crossref","first-page":"506324","DOI":"10.1155\/2013\/506324","article-title":"Decursin and doxorubicin are in synergy for the induction of apoptosis via STAT3 and\/or mTOR pathways in human multiple myeloma cells","volume":"2013","author":"Jang","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.clml.2018.03.007_bib64","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1182\/blood-2002-02-0376","article-title":"2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells","volume":"100","author":"Chauhan","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib65","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2018.03.007_bib66","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1126\/science.274.5293.1652","article-title":"How proteolysis drives the cell cycle","volume":"274","author":"King","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.clml.2018.03.007_bib67","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2018.03.007_bib68","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib69","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1128\/MCB.18.7.3659","article-title":"Cyclin-stimulated binding of Cks proteins to cyclin-dependent kinases","volume":"18","author":"Egan","year":"1998","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clml.2018.03.007_bib70","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18632\/oncotarget.105","article-title":"Over-expression of CKS1B activates both MEK\/ERK and JAK\/STAT3 signaling pathways and promotes myeloma cell drug-resistance","volume":"1","author":"Shi","year":"2010","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2018.03.007_bib71","first-page":"271","article-title":"Flow cytometric analysis of DNA indices, expression of p53 and multidrug resistance genes in multiple myeloma patients","volume":"26","author":"Kumar","year":"2004","journal-title":"Anal Quant Cytol Histol"},{"key":"10.1016\/j.clml.2018.03.007_bib72","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0921-8777(01)00092-1","article-title":"Repair of DNA interstrand cross-links","volume":"486","author":"Dronkert","year":"2001","journal-title":"Mutat Res"},{"key":"10.1016\/j.clml.2018.03.007_bib73","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00277-009-0831-6","article-title":"Reversal of multidrug resistance by curcumin through FA\/BRCA pathway in multiple myeloma cell line MOLP-2\/R","volume":"89","author":"Xiao","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2018.03.007_bib74","doi-asserted-by":"crossref","first-page":"e55493","DOI":"10.1371\/journal.pone.0055493","article-title":"An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells","volume":"8","author":"Sousa","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2018.03.007_bib75","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/1523-1747.ep12332650","article-title":"Fibronectin suppresses apoptosis in normal human melanocytes through an integrin-dependent mechanism","volume":"108","author":"Scott","year":"1997","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.clml.2018.03.007_bib76","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1038\/sj.onc.1203782","article-title":"Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)","volume":"19","author":"Hazlehurst","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2018.03.007_bib77","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood-2003-07-2340","article-title":"Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines","volume":"103","author":"Nefedova","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib78","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1038\/sj.onc.1205325","article-title":"Cell cycle regulators and hematopoiesis","volume":"21","author":"Steinman","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2018.03.007_bib79","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1182\/blood-2005-01-0049","article-title":"Wnts induce migration and invasion of myeloma plasma cells","volume":"106","author":"Qiang","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib80","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood-2008-12-194290","article-title":"Aurora kinase A is a target of Wnt\/beta-catenin involved in multiple myeloma disease progression","volume":"114","author":"Dutta-Simmons","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib81","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1038\/bcj.2011.41","article-title":"AV-65, a novel Wnt\/beta-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model","volume":"1","author":"Yao","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2018.03.007_bib82","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/leu.2013.174","article-title":"Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications","volume":"28","author":"Bjorklund","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.007_bib83","doi-asserted-by":"crossref","first-page":"11009","DOI":"10.1074\/jbc.M110.180208","article-title":"Evidence of a role for activation of Wnt\/beta-catenin signaling in the resistance of plasma cells to lenalidomide","volume":"286","author":"Bjorklund","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2018.03.007_bib84","first-page":"887","article-title":"Targeting the Wnt\/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model","volume":"25","author":"Kim","year":"2011","journal-title":"In\u00a0Vivo"},{"key":"10.1016\/j.clml.2018.03.007_bib85","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1074-7613(00)80501-4","article-title":"Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis","volume":"5","author":"Fukada","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.clml.2018.03.007_bib86","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1182\/blood.V93.9.3044","article-title":"Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2","volume":"93","author":"Feinman","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib87","first-page":"2221","article-title":"PC cell-derived growth factor (granulin precursor) expression and action in human multiple myeloma","volume":"9","author":"Wang","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.03.007_bib88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/1078-0432.CCR-05-0929","article-title":"PC cell-derived growth factor confers resistance to dexamethasone and promotes tumorigenesis in human multiple myeloma","volume":"12","author":"Wang","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.03.007_bib89","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1182\/blood-2010-05-285726","article-title":"Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor","volume":"116","author":"Hoang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib90","doi-asserted-by":"crossref","first-page":"21796","DOI":"10.1074\/jbc.M111.304626","volume":"287","author":"Hoang","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2018.03.007_bib91","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1158\/1078-0432.CCR-04-0874","article-title":"A\u00a0selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells","volume":"10","author":"Hov","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.03.007_bib92","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-13-0039","article-title":"Novel Targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma","volume":"19","author":"Moschetta","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.03.007_bib93","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2050-7771-2-10","article-title":"Micro-RNAs, new performers in multiple myeloma bone marrow microenvironment","volume":"2","author":"Abdi","year":"2014","journal-title":"Biomark Res"},{"key":"10.1016\/j.clml.2018.03.007_bib94","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrd3179","article-title":"Targeting microRNAs in cancer: rationale, strategies and challenges","volume":"9","author":"Garzon","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clml.2018.03.007_bib95","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-12-3325","article-title":"Targeting miR-21 inhibits in\u00a0vitro and in\u00a0vivo multiple myeloma cell growth","volume":"19","author":"Leone","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.03.007_bib96","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1756-8722-4-37","article-title":"Suppressing miRNA-15a\/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells","volume":"4","author":"Hao","year":"2011","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2018.03.007_bib97","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood-2007-03-081133","article-title":"Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer","volume":"110","author":"Loffler","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib98","first-page":"217365","article-title":"Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma","volume":"2014","author":"Scognamiglio","year":"2014","journal-title":"Blood Res Int"},{"key":"10.1016\/j.clml.2018.03.007_bib99","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1158\/1078-0432.CCR-12-1708","article-title":"Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in\u00a0vitro and in\u00a0vivo evidence","volume":"18","author":"Di Martino","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.03.007_bib100","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.4161\/cc.25251","article-title":"Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression","volume":"12","author":"Murray","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.clml.2018.03.007_bib101","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1038\/cddis.2012.175","article-title":"miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1","volume":"3","author":"Amodio","year":"2012","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.clml.2018.03.007_bib102","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s12672-011-0072-8","article-title":"Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma","volume":"2","author":"Tessel","year":"2011","journal-title":"Horm Cancer"},{"key":"10.1016\/j.clml.2018.03.007_bib103","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sj.onc.1208982","article-title":"Increased susceptibility to apoptosis in CD45(+) myeloma cells accompanied by the increased expression of VDAC1","volume":"25","author":"Liu","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2018.03.007_bib104","first-page":"266","article-title":"Osteogenic inhibition in multiple myeloma","volume":"15","author":"Habibi","year":"2013","journal-title":"Cell J"},{"key":"10.1016\/j.clml.2018.03.007_bib105","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2141.2008.07252.x","article-title":"Galectin-1 supports the survival of CD45RA(-) primary myeloma cells in\u00a0vitro","volume":"142","author":"Abroun","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.03.007_bib106","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood.V82.2.564.564","article-title":"Identification of immature and mature myeloma cells in the bone marrow of human myelomas","volume":"82","author":"Kawano","year":"1993","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2018.03.007_bib107","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF03165278","article-title":"Growth mechanism of human myeloma cells by interleukin-6","volume":"76","author":"Kawano","year":"2002","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2018.03.007_bib108","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/10245330310001621305","article-title":"The regulatory mechanism of IL-6-dependent proliferation of human myeloma cells","volume":"8","author":"Tsuyama","year":"2003","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2018.03.007_bib109","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2004-10-3915","article-title":"Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells","volume":"105","author":"Ma","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.leu.2404462","article-title":"PPARbeta-mediated growth suppression of baicalein and dexamethasone in human myeloma cells","volume":"21","author":"Otsuyama","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.007_bib111","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1158\/0008-5472.CAN-04-3079","article-title":"Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma","volume":"65","author":"Liu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2018.03.007_bib112","doi-asserted-by":"crossref","first-page":"81926","DOI":"10.18632\/oncotarget.10745","article-title":"Kinase inhibitors as potential agents in the treatment of multiple myeloma","volume":"7","author":"Abramson","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2018.03.007_bib113","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib114","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clml.2018.03.007_bib115","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.007_bib116","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/17474086.2017.1326814","article-title":"How is patient care for multiple myeloma advancing?","volume":"10","author":"Genadieva Stavric","year":"2017","journal-title":"Exp Rev Hematol"},{"key":"10.1016\/j.clml.2018.03.007_bib117","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12185-016-2008-0","article-title":"Histone deacetylase inhibitors in multiple myeloma: from bench to bedside","volume":"104","author":"Harada","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2018.03.007_bib118","first-page":"822","article-title":"Gene expression status and methylation pattern in promoter of P15INK4b and P16INK4a in cord blood CD34+ stem cells","volume":"16","author":"Azad","year":"2013","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.clml.2018.03.007_bib119","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/leu.2011.214","article-title":"Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma","volume":"26","author":"Van De Donk","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.007_bib120","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/1060028016642786","article-title":"Immunotherapy: a new approach to treating multiple myeloma with daratumumab and elotuzumab","volume":"50","author":"Afifi","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clml.2018.03.007_bib121","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.imlet.2010.09.021","article-title":"Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: from pro-B to plasma cells","volume":"134","author":"De Salort","year":"2011","journal-title":"Immunol Lett"},{"key":"10.1016\/j.clml.2018.03.007_bib122","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ni.1693","article-title":"Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function","volume":"10","author":"Cruz-Munoz","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clml.2018.03.007_bib123","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1128\/MCB.01107-14","article-title":"Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells","volume":"35","author":"Guo","year":"2015","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clml.2018.03.007_bib124","doi-asserted-by":"crossref","first-page":"879","DOI":"10.7314\/APJCP.2016.17.3.879","article-title":"Microchips and their significance in isolation of circulating tumor cells and monitoring of cancers","volume":"17","author":"Sahmani","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clml.2018.03.007_bib125","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3960\/jslrt.56.20","article-title":"The role of intracellular signaling pathways in the pathogenesis of multiple myeloma and novel therapeutic approaches","volume":"56","author":"Kizaki","year":"2016","journal-title":"J\u00a0Clin Exp Hematopathol"},{"key":"10.1016\/j.clml.2018.03.007_bib126","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clml.2018.03.007_bib127","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.exphem.2015.04.010","article-title":"Novel therapeutic strategies for multiple myeloma","volume":"43","author":"Mimura","year":"2015","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2018.03.007_bib128","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1158\/0008-5472.CAN-06-4361","article-title":"Inhibition of p38\u03b1 mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma","volume":"67","author":"Vanderkerken","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2018.03.007_bib129","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2141.2008.07044.x","article-title":"p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma: therapeutic implications","volume":"141","author":"Ishitsuka","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.03.007_bib130","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/leu.2011.192","article-title":"MRK003, a \u03b3-secretase inhibitor exhibits promising in\u00a0vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma","volume":"26","author":"Ramakrishnan","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.007_bib131","first-page":"88","article-title":"Short view of leukemia diagnosis and treatment in Iran","volume":"9","author":"Azad","year":"2015","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"10.1016\/j.clml.2018.03.007_bib132","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.hemonc.2017.05.005","article-title":"Recent advances in understanding multiple myeloma","volume":"10","author":"Hari","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017319523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017319523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:42Z","timestamp":1761870642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017319523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":132,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S2152265017319523"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.03.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}